Market Intelligence, Preclinical Progress, and High-Purity Reagents for PP2A Pathway Modulation in Oncology and Neurodegeneration.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LCMT1 methyltransferase drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| LCMT1 (Wild-Type) | LCMT1 Recombinant Protein (Wild-Type). High purity (>95%), Sequence Verified. E. coli/HEK293 expressed for native folding. Suitable for SAM-dependent methyltransferase assays. | View LCMT1 Products |
| LCMT1 (Mutant) | LCMT1 Mutant Recombinant Protein (Catalytic Dead / SAM-Pocket). For negative control, selectivity counter-screening, and resistance modeling. Includes D296A and SAM-binding mutants. | View LCMT1 Products |
| Paralog Control | LCMT2 Recombinant Protein. For selectivity counter-screening vs LCMT1. Sequence Verified. | View LCMT2 Products |
| Substrate | PPP2CA (PP2A Catalytic Subunit) Recombinant Protein. Native substrate for LCMT1 methyltransferase assays. Unmethylated form for competition studies. | View PPP2CA Products |
| Gene Delivery | LCMT1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction and target engagement studies. | View LCMT1 Products |
| Benchmark Antibody | Anti-LCMT1 Monoclonal/Polyclonal Antibody. Research-grade recombinant binder for Western Blot, IHC, ELISA, and target engagement validation. | View LCMT1 Products |
| Validator (siRNA) | LCMT1 siRNA Set (pre-validated sequences). For knockdown verification, loss-of-function studies, and specificity checks. | View LCMT1 Products |
| Related Target: PPME1 | PPME1 (PP2A Methylesterase 1) Recombinant Protein. Opposing enzyme that demethylates PP2A; critical for dynamic methylation balance studies. | View PPME1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Purity & activity of LCMT1 for HTS campaigns | LCMT1 WT Protein >95% purity, Endotoxin controlled (<1EU/μg), Sequence Verified, suitable for SAM-dependent methyltransferase assays |
| Selectivity counter-screening vs other MTases (including paralog LCMT2) | LCMT1 Active-Site Mutant and structural-grade WT protein; Purified LCMT1 and LCMT2 proteins available side-by-side for cross-reactivity evaluation |
| Coupled methyltransferase assay requiring native substrate | Human PPP2CA Recombinant Protein (unmethylated) available for direct methylation readout (anti-methyl-Leu309 detection) |
| Cellular target engagement & pathway modulation | LCMT1 Lentivirus for stable overexpression or rescue experiments; compatible with methyl-PP2AC Western/IP |
| False positives from non-specific inhibitors | Validated LCMT1 siRNA included for genetic confirmation of on-target activity; Endotoxin controlled to prevent artifactual signaling |
| Mechanism of action validation | Catalytically dead mutants (e.g., D296A) available as negative controls; SAM-binding mutants for mechanistic studies |
Live LCMT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
LCMT1 sits at a critical node in the PP2A tumor suppressor axis, controlling the methylation and trimeric assembly of PP2A holoenzymes. Its role as a master regulator of PP2A makes it a strategic target across oncology (where PP2A dysregulation drives tumorigenesis) and neurodegeneration (where tau phosphorylation is involved). While direct clinical candidates remain in early discovery, the race for LCMT1-directed therapeutics is intensifying around small-molecule allosteric regulators, PROTAC-mediated degradation, and blood-brain barrier penetrant inhibitors. The next wave of R&D focuses on achieving selectivity over the closely related LCMT2 paralog and designing compounds that can restore the LCMT1-PP2A-PME-1 dynamic equilibrium in therapy-resistant cancers and Alzheimer's disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Activator/Inhibitor) | Discovery-stage biotechs & academic consortia | Solid tumors, Hematologic malignancies, Alzheimer's | Biochemical methyltransferase assay (Need high-purity LCMT1 WT & mutant proteins) |
| PROTAC / Degrader | Emerging biotech platforms, Preclinical innovators | Refractory cancers, PP2A-dysregulated tumors | Ternary complex formation assays, ubiquitination assays (Need purified LCMT1 for SPR/Native MS) |
| Molecular Glue | Exploratory academic programs | Refractory solid tumors | Structural co-complex validation (Need crystallography-grade LCMT1) |
| Gene Therapy | Translational research | Neurodegeneration (AD, PD) | Viral vectors (Lentivirus/AAV) for stable in vivo expression |
| Chemical Probes | SGC, NIH Initiative | Target validation | Selectivity panel (LCMT1 vs LCMT2 ortholog proteins) |
| Allosteric Modulators | Early discovery | Solid tumors, Alzheimer's | Conformational assay (Need full-length recombinant protein) |